SynthesisFrontiers in immunology2025

CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis.

Ying He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.